Category Specific RSS

asx cov

CLEO meets with US FDA to develop strategy for ovarian cancer test launch

Ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV) has taken a major step towards the US launch of its pre-surgical…

1 year ago

Cleo’s ovarian cancer blood test proves more effective than CA125 clinical benchmark and ultrasound

A benchmarking study comparing ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV)’s blood test against ultrasound has been published in…

1 year ago

Cleo Diagnostics progresses ovarian cancer test kits for US, Australia, and EU markets

Just two months after it first floated on the ASX, ovarian cancer diagnostics company Cleo Diagnostics (ASX: COV).

2 years ago

IPO Watch: Cleo Diagnostics to go public with ovarian cancer test kits to address 51% survival rate

As diseases continue to adapt, the realm of medical diagnostics must intelligently progress to adeptly combat these changes. Timely interventions…

2 years ago